Home / Market News / $ADAG
benzinga Corporate Catalyst Impact 65/100 ● neutral

China’s NMPA Approves Adagene’s IND Application For ADG138, Double-Masked HER2×CD3 Bispecific T Cell Engager Built On Proprietary SAFEbody Precision Masking Technology

Sep 22, 2026, 12:02 PM UTC · Primary ticker $ADAG

Adagene announced that China's NMPA has approved its Investigational New Drug (IND) application for ADG138, a bispecific T cell engager. This approval allows Adagene to proceed with a Phase 1 clinical trial for advanced solid tumors, which is expected to begin in Q4 2026, marking a significant step in the drug's development.

Adagene announced the NMPA approval of its IND application for ADG138, a double-masked HER2×CD3 bispecific T cell engager. This approval is a crucial regulatory milestone, allowing the company to initiate a Phase 1 clinical trial in China for advanced solid tumors, projected for Q4 2026. This news is positive for Adagene as it validates their proprietary SAFEbody technology and moves a promising drug candidate closer to market. While the immediate market impact might be moderate given the early stage of development (Phase 1), it represents a long-term opportunity for the company if ADG138 demonstrates efficacy and safety in human trials. The key risk lies in the lengthy and uncertain clinical trial process, but this approval is a de-risking event for the initial development phase.

$ADAG positive IND approval for key drug candidate
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.